Poolbeg Pharma PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POLBF research report →
Companywww.poolbegpharma.com
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
- CEO
- Jeremy Skillington
- IPO
- 2022
- Employees
- 15
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $43.78M
- P/E
- -5.93
- P/S
- 0.00
- P/B
- 3.93
- EV/EBITDA
- -4.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -55.47%
- ROIC
- -73.60%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,694,077 · 1.66%
- EPS
- $-0.01 · 18.97%
- Op Income
- $-6,416,959
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.20
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.05
- Beta
- 1.77
- Avg Volume
- 486
Get TickerSpark's AI analysis on POLBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our POLBF Coverage
We haven't published any research on POLBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate POLBF Report →